Although activating mutations, such as L1195V/F and D1228N/H, can cause resistance to MET-TKIs, it is still unclear whether MET TKD mutations confer resistance in NSCLC patients independent of MET inhibition. This evidence concerns the gene MET and non-small cell lung carcinoma.